Shares of Teva are up more than 5 percent this morning after Israeli media reported billionaire businessman Len Blavatnik is considering taking a large stock position in the pharma giant.…

Neurocrine's third-quarter financial results didn't just impress, they blew everybody away. Source: BioSpace

Mr. Guindo brings 27 years of experience in the global pharma industry and has held several leadership positions at Merck. Source: BioSpace

Gilead Sciences' third-quarter financial results were dismal, to say the least. Source: BioSpace

The acquisition is expected to close by the end of 2017. Source: BioSpace

CryoPort handles the products for more than 172 of the more than 800 immunotherapy trials underway. Source: BioSpace

The MAA will be reviewed under the EMA's Accelerated Assessment program. Source: BioSpace

Moderna CEO said the company was not likely to float its initial public offering until the company has solid data on its lead mRNA treatment. Source: BioSpace

A little more than one year after securing $130M in financing, molecular technology company Zymergen has expanded beyond the Golden State to the Emerald City, Seattle. Source: BioSpace

Alnylam and Sanofi Genzyme presented positive Phase III results of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy at a conference in France. Source: BioSpace